Daphnicyclidin I exhibits significant neuropharmacological activity, primarily acting as a potent modulator of ion channels in the central nervous system. It has been investigated for its potential use in treating neurodegenerative disorders due to its ability to enhance neuronal signaling and protect against excitotoxicity. Research suggests it may play a role in improving cognitive function and memory retention, making it a candidate for further development in therapies targeting Alzheimer’s disease and related conditions. Additionally, its unique structure allows for high blood-brain barrier permeability, which enhances its effectiveness in central nervous system applications. Studies are ongoing to evaluate its safety and efficacy in preclinical models.